1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kadimastem Ltd

Kadimastem Ltd

KMSTF
Kadimastem LtdUS flagOther OTC
3.21
USD
-0.10
- -
9.50MMarket Cap
Kadimastem Ltd
KMSTF
(Other OTC)

Recent

price

3.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
0.67
0.9
5.11
8.83
2.72
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-35.17
-42.36
-84.88
-103.57
-85.37
-36.39
-23.88
-14.36
-11.09
-6.44
-2.83
-6.33
Basic EPS, GAAP
-39.55
-28.15
-57.81
-73.08
-79.62
-32.82
-20.81
-14.53
-9.32
-5.85
-2.62
-0.66
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-159.13
-368.99
-488.51
-459.55
-211.18
-156.23
-122.32
-88.58
-65.77
-57.39
-64.4
Book Value per Share
- -
4.31
-5.09
-44.37
17.05
10.23
-11.45
-5.33
6.49
0.09
-1.03
-6.95
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
1
2
2
4
4
4
Basic Weighted Avg Shares
- -
- -
1
2
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-6,311.67
-4,823.53
-1,500.1
-1,137.35
-3,046.35
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
1
1
1
1
1
- -
1
2
2
2
2
2
Depreciation Expense
-13
-15
-17
-20
-21
-24
-25
-22
-26
-23
-12
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5,255.83
-4,703.1
-1,659.92
-1,172.81
-3,132.75
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-3
-8
3
5
-15
-11
13
-3
-7
-30
Working Capital
- -
- -
- -
2
- -
- -
2
1
- -
2
1
- -
LT Debt
- -
2
-1
-9
4
7
-12
-8
15
- -
-4
-29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-109.14%
-258.11%
568.49%
Free Cash Flow
-3.92%
-25.35%
-75.01%
Net Income, GAAP
12.12%
13.6%
121.1%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.83
2024
- -
- -
- -
- -
-6.33
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Histogen Inc. (HSTO)
BenevolentAI S.A. (BAI.AS)
Alzamend Neuro Inc (ALZN)
Agentix Corp. (AGTX)
Yumanity Therapeutics, Inc. (YMTX)
SMS Lifesciences India Limited (SMSLIFE.NS)
Business
Kadimastem Ltd (TASE: KDST; OTC: KMSTF) is a clinical-stage biotechnology company that develops off-the-shelf, allogeneic cell therapies derived from human embryonic stem cells (hESCs) for neurodegenerative and metabolic diseases; its lead product candidates include AstroRx, functional astrocytes in Phase 2a clinical development for amyotrophic lateral sclerosis (ALS) and preclinical studies for other neurodegenerative indications, and IsletRx, functional pancreatic islet cells producing insulin and glucagon for the treatment of insulin-dependent Type 1 diabetes without lifelong immunosuppression. Founded in 2008 and headquartered in Ness Ziona, Israel, the company leverages a proprietary platform for scalable production of differentiated cells under GMP conditions, targeting patients with unmet needs in ALS and diabetes through transplantation of lab-differentiated, mature functional cells. In October 2025, Kadimastem completed a merger with NLS Pharmaceutics Ltd, forming NewcelX Ltd (Nasdaq: NCEL), headquartered in Zurich, Switzerland, with research operations in Ness Ziona; Kadimastem shareholders now hold approximately 85% of the combined entity, which integrates cell therapy expertise with small-molecule neuroscience programs and plans to advance AstroRx Phase 2a trials and IsletRx Phase 1 studies. Recent developments include a strategic collaboration with TargetGene announced in October 2025 to develop next-generation gene-edited cell therapies under NewcelX, up to $28 million in equity financing in March 2025 to support the merger and clinical programs, and continued BIRD Foundation support for the ITOL-102 diabetes program post-merger. NewcelX operates globally with a focus on regenerative medicine, led by Executive Chairman and CEO Ronen Twito and Chief Scientific Officer Prof. Michel Revel.

Company News

APIChatGPT

  • prnewswire.com

    NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.